DekaBank Deutsche Girozentrale
STOK icon

DekaBank Deutsche Girozentrale’s Stoke Therapeutics STOK Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,000
Closed -$257K – 1399
2022
Q3 		$257K Buy
20,000
+10,000
+100% +$159K ﹤0.01% 1181
2022
Q2 		$130K Hold
10,000
– – ﹤0.01% 1261
2022
Q1 		$222K Buy
10,000
+900
+10% +$18K ﹤0.01% 1191
2021
Q4 		$205K Buy
9,100
+200
+2% +$4.77K ﹤0.01% 1266
2021
Q3 		$227K Hold
8,900
– – ﹤0.01% 1184
2021
Q2 		$291K Hold
8,900
– – ﹤0.01% 1152
2021
Q1 		$328K Hold
8,900
– – ﹤0.01% 1101
2020
Q4 		$523K Hold
8,900
– – ﹤0.01% 1012
2020
Q3 		$303K Buy
+8,900
New +$254K ﹤0.01% 994

Other funds holding STOK

ST
Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

DekaBank Deutsche Girozentrale's STOK Position: Q4 2022 in Review

DekaBank Deutsche Girozentrale sold out of Stoke Therapeutics (STOK) in Q4 2022, closing a stake of 20,000 shares — an estimated $257K sold.

DekaBank Deutsche Girozentrale first reported a position in STOK in Q3 2020 and held it in 9 quarters. The position peaked at $523K in Q4 2020. 107 funds tracked by Wall St. Rank hold STOK as of Q4 2022.

  • DekaBank Deutsche Girozentrale reported no remaining Stoke Therapeutics position as of Q4 2022 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 20,000 Stoke Therapeutics shares in Q4 2022, an estimated $257K.
  • DekaBank Deutsche Girozentrale first reported a position in Stoke Therapeutics in Q3 2020 and held it in 9 quarters.
  • DekaBank Deutsche Girozentrale's Stoke Therapeutics position peaked at $523K in Q4 2020.
  • 107 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q4 2022.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q4 2022, filed 1 Feb 2023.